Ketamine changes depression’s symptoms, biology
This image was generated by AI and may not depict real events.
Ketamine has been found to offer rapid relief from depressive symptoms in hours to days, challenging the traditional understanding of depression focused on serotonin and other monoamines. Research suggests that ketamine may enhance neuroplasticity by activating AMPAR receptors, providing new insights into the biology of depression.
Ketamine, an FDA-approved anesthetic, has been shown to provide rapid relief from depressive symptoms. It has been found to enhance neuroplasticity by activating AMPAR receptors, a key component of glutamate signaling. A recent study used positron emission tomography imaging to visualize activity at AMPARs in the living human brain. The study found that patients with treatment-resistant depression demonstrated altered AMPAR patterns in brain regions associated with mood regulation. After ketamine treatment, these receptor patterns shifted, correlating with improvements in depressive symptoms. This research provides new insights into the biology of depression, suggesting that it may involve disruptions in neural plasticity rather than simply imbalances in chemicals.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.